The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decon
...
tamination before disposal;
personal protective equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so
...
cial disruption and economic consequences of COVID-19, curtail the emergence of new SARS-CoV-2 variants of concern (VOCs) and ultimately control the pandemic.
more
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.
The number of COVID-19 cases is on the rise again, with South Africa nearing half of all confirmed cases in the WHO African Region. Threats of new variants loom and low vaccination coverage raises questions on the future of the response to COVID-19.
...
Prevention remains the key strategy in most sub-Saharan countries. Five National Centres (NCs) from the African Health Observatory Platform on Health Systems and Policies (AHOP), based in Ethiopia, Kenya, Nigeria, Rwanda and Senegal, reflect on lessons to be learnt from their containment responses in the initial phases. They construct timelines to highlight the policies and challenges associated with introducing a range of public health containment measures and
discuss the extent to which these measures continue to be valuable given the ever-changing nature of the pandemic.
more
Le nombre de cas de COVID-19 augmente à nouveau, l’Afrique du Sud comptant pour près de la moitié de tous les cas confirmés de la Région africaine de l’OMS. La menace de nouveaux variants plane, et la faible couverture vaccinale soulève de
...
s questions concernant les mesures qui devront être prises pour lutter contre la COVID-19. Dans la plupart des pays d’Afrique subsaharienne, la prévention reste la stratégie clé. Dans ce document, cinq centres nationaux de la plateforme de l’Observatoire africain de la santé sur les systèmes et politiques de santé (AHOP), basés en Éthiopie, au Kenya, au Nigéria, au Rwanda et au Sénégal analysent les leçons à tirer de leurs mesures d’endiguement respectives lors despremières phases de la pandémie.
more
Leptospirosis is a zoonotic disease with epidemic potential, especially after a heavy rainfall,
caused by a bacterium called Leptospira. Leptospira interrogans is pathogenic to humans and
animals, with more than 200 serologic variants or serovars.
...
Humans usually acquire
leptospirosis through direct contact with the urine of infected animals or a urine-contaminated
environment. Human-to-human transmission occurs only very rarely. Leptospirosis may present
with a wide variety of clinical manifestations, from a mild illness that may progress to a serious
and sometimes fatal disease. Its symptoms may mimic many diseases, such as influenza,
dengue and other viral haemorrhagic diseases; making the correct diagnosis (clinical and
laboratory) at the onset of symptoms is important to prevent severe cases and save lives,
primarily in outbreak situations.
more
Orientations provisoires, 28 janvier 2021
Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de
...
sécurité biologique relatifs à la réalisation des tests diagnostiques rapides antigéniques, manipulation des nouveaux variants du SARS-CoV-2 au laboratoire, mise à jour de la décontamination des tests avant leur élimination, équipement de protection individuelle (EPI) pour le prélèvement d’échantillons et, même s’ils ne concernent pas directement la sécurité biologique, dangers chimiques et leur élimination en toute sécurité.
more
23 Dec 2020. The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, based on the experience in the EU from August–December, 2020. This document also addresses transmissio
...
n to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing and the efficacy of partial and full school closures. This document draws upon and updates evidence presented in the previous report from ECDC on this topic, which was published on August 6, 2020
more
WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI
...
D-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts.
more
The New England Journal of Medicine
Genetic analysis of the virus indicates that it is closely related (97% identical) to variants of Ebola virus (species Zaire ebolavirus) identified earlier in the Democratic Republic of the Congo and Gabon
PLEAS
...
E download the article from the website!!
more
Are the symptoms of COVID-19 different in children? Do the new variants impact children differently? What can parents do to keep children safe from COVID-19. WHO's Dr Maria Van Kerkhove explains in Science in 5.
Science in 5 is WHO’s conversa
...
tions in science. Watch WHO experts explain science related to COVID-19.
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decon
...
tamination before disposal;
personal protective equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decon
...
tamination before disposal;
personal protective equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
Trachoma causes more vision loss and blindness than any other infection in the world. This disease is caused by Chlamydia trachomatis bacteria. Other variants or strains of these bacteria can cause a sexually transmitted infection (chlamydia) and di
...
sease in lymph nodes.
This is photomicrograph of a conjunctival smear that revealed the presence of what are known as, intracytoplasmic inclusions Trachoma is easily spread through direct personal contact such as from fingers, through shared towels and clothes, and through flies that have been in contact with the eyes or nose of an infected person. When left untreated, repeated Chlamydia trachomatis infections in the eye can cause severe scarring on the inside of the eyelid. This can cause the eyelashes to scratch the cornea (trichiasis). In addition to causing pain, trichiasis permanently damages the cornea and can lead to irreversible blindness.
Chlamydia trachomatis infections spread in areas that lack access to safely managed drinking water and sanitation systems. Trachoma affects the most resource-limited communities in the world. Globally, almost 1.9 million people have vision loss because of trachoma, and it causes 1.4% of all blindness worldwide.1 In 2021, 136 million people lived in trachoma-endemic areas and were at risk of trachoma blindness.
more
Over 18 months into the pandemic, WHO continues to conductglobal surveillance of COVID-19as part of activities on preparedness, readiness and response activities. The need for global surveillance of COVID-19 is greater than ever, asthe implementation of vaccination campaigns and the appearance of
...
variants are prone to impact the course of the epidemic, as transmission patterns evolve. Timely and complete surveillance data are key to monitoring these changes.
Features include stratification by age and sex, trends over time, case fatality ratios by age, testing, hospitalization, and data on health workers –all visible at country and regional levels. The dashboard provides the ability for users to conduct further analyses by country and selected time period.
more
Lorsqu’un virus circule largement dans une population et entraîne de nombreuses infections, la probabilité de mutation augmente. Plus un virus a de possibilités de se propager, plus il se réplique – et plus il est susceptible de muter. L’arrêt de la propagation du virus à la source res
...
te essentiel. Les mesures actuelles visant à réduire la transmission du virus – dont le lavage fréquent des mains, le port du masque, la distanciation physique et le fait d’éviter de se rendre dans les lieux très fréquentés ou fermés – restent efficaces contre les nouveaux variants car elles réduisent la transmission du virus, qui a donc moins de possibilités de muter. Grâce aux notes explicatives de l’OMS sur les vaccins, en savoir plus sur les vaccins, sur leur fonctionnement et sur la façon dont ils sont fabriqués pour en garantir l’innocuité et y permettre un accès équitable.
more
n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t
...
racing, and clinical management. The Test to Treat guideline aims to increase continental testing efforts and reduce COVID-19 transmission in Africa and put-up response measures to control the impact of the virus, both to limit spread and to reduce substantially the risks of severe health outcomes related to COVID-19 infection. These countermeasures include highly effective vaccines and boosters, rapid testing options for monitoring exposure, and effective therapeutic options for both pre-exposure prevention and treatment of mild-to-moderate disease, oxygen therapy for moderate-severe disease, all of which can potentially be updated efficiently as new variants emerge that may affect the effectiveness of the available tools.
more